Cervical cancer natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (59 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cervical cancer}} | {{Cervical cancer}} | ||
{{CMG}}{{AE}}{{Nnasiri}} | |||
==Overview== | |||
Cervical cancer is the most common [[cancer]] mainly among women in developing countries, there is an estimate of almost 260,000 deaths annually, about 80% occurred in developing countries. Common complications of cervical cancer include [[pain]], [[vaginal bleeding]], [[fistula]] and [[renal failure]]. | |||
[[Prognosis]] is generally good, and the 5 year [[survival rate]] of patients with cervical cancer is approximately 70%. Studies has proven that there is an association between age of the patients and socioeconomic status of women with higher incidence of [[infection]] with high risk [[HPV]] in underserved poulation in the US. | |||
{{ | ==Natural history== | ||
* Cervical cancer is the most common cancer mainly among women in developing countries, there is an estimate of almost 260,000 deaths annually, about 80% occurred in developing countries.<ref name="pmid11577044">{{cite journal |vauthors=Sherris J, Herdman C, Elias C |title=Cervical cancer in the developing world |journal=West. J. Med. |volume=175 |issue=4 |pages=231–3 |date=October 2001 |pmid=11577044 |pmc=1071564 |doi= |url=}}</ref> | |||
* [[Infection]] by high risk strain of [[oncogenic]] [[HPV]] types is an established cause of neoplastic lesions of the [[cervix]], [[vagina]] and [[vulva]], [[anus]], [[penis]] and [[oropharynx]]. [[HPV]] 16 and 18, are the most common cause of approximately 70% of all cervical cancers worldwide. [[HPV]] is highly transmissible through direct [[skin]] to [[skin]] contact and [[intercourse]], women with persistent high-risk [[HPV]] [[infection]]<nowiki/>s are at greatest risk for developing cervical cancer. | |||
* Since the identification of [[HPV]] as main cause of cervical cancer, [[prevention]] strategies had been developed by the introduction of [[HPV]] testing and [[cytology]] screening and utilizing [[HPV]] [[vaccines]] in [[preadolescent]] girls and young women whom are at greater risk.<ref name="BoschBroker2013">{{cite journal|last1=Bosch|first1=F. Xavier|last2=Broker|first2=Thomas R.|last3=Forman|first3=David|last4=Moscicki|first4=Anna-Barbara|last5=Gillison|first5=Maura L.|last6=Doorbar|first6=John|last7=Stern|first7=Peter L.|last8=Stanley|first8=Margaret|last9=Arbyn|first9=Marc|last10=Poljak|first10=Mario|last11=Cuzick|first11=Jack|last12=Castle|first12=Philip E.|last13=Schiller|first13=John T.|last14=Markowitz|first14=Lauri E.|last15=Fisher|first15=William A.|last16=Canfell|first16=Karen|last17=Denny|first17=Lynette A.|last18=Franco|first18=Eduardo L.|last19=Steben|first19=Marc|last20=Kane|first20=Mark A.|last21=Schiffman|first21=Mark|last22=Meijer|first22=Chris J.L.M.|last23=Sankaranarayanan|first23=Rengaswamy|last24=Castellsagué|first24=Xavier|last25=Kim|first25=Jane J.|last26=Brotons|first26=Maria|last27=Alemany|first27=Laia|last28=Albero|first28=Ginesa|last29=Diaz|first29=Mireia|last30=Sanjosé|first30=Silvia de|title=Comprehensive Control of Human Papillomavirus Infections and Related Diseases|journal=Vaccine|volume=31|year=2013|pages=I1–I31|issn=0264410X|doi=10.1016/j.vaccine.2013.07.026}}</ref> | |||
* The most important risk factors associated with the [[infection]] by [[HPV]] are sexual intercourse at early age at the start of the first sexual relationships, having high number of sexual partners throughout life, or women being with men having multiple sexual partners. [[Male]] circumcision and use of condoms are factors that can reduce, but not preventing the transmission of [[human papilloma virus]].<ref name="Castellsagué2008">{{cite journal|last1=Castellsagué|first1=Xavier|title=Natural history and epidemiology of HPV infection and cervical cancer|journal=Gynecologic Oncology|volume=110|issue=3|year=2008|pages=S4–S7|issn=00908258|doi=10.1016/j.ygyno.2008.07.045}}</ref> | |||
* There is an association between age and socioeconomic status of women in underserved areas of the US and higher [[incidence]] of infection with HPV. <ref name="pmid28410118">{{cite journal |vauthors=Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, Jaggi M, Chauhan SC |title=Disparity in rates of HPV infection and cervical cancer in underserved US populations |journal=Front Biosci (Schol Ed) |volume=9 |issue= |pages=254–269 |date=June 2017 |pmid=28410118 |pmc=5935458 |doi= |url=}}</ref> | |||
==Complications== | ==Complications== | ||
Advanced stage of cervical cancer can cause varieties of complications, some of these are include:<ref name="SchmitzIsaacs1957">{{cite journal|last1=Schmitz|first1=Herbert E.|last2=Isaacs|first2=John H.|title=Complications of Advanced Cervical Cancer and Their Management|journal=Radiology|volume=69|issue=3|year=1957|pages=324–329|issn=0033-8419|doi=10.1148/69.3.324}}</ref> | |||
* [[Pain]] | |||
* Vaginal [[hemorrhage]] | |||
* Enterovaginal, [[Rectovaginal fistula|rectovaginal]], and vesico- or ureterovaginal [[fistula]]<nowiki/>s | |||
* [[Renal failure]] and/or [[uremia]] | |||
* [[Malnutrition]] | |||
* [[Anemia]] | |||
* Mental [[depression]] | |||
* | * | ||
==Prognosis== | ==Prognosis== | ||
* The [[prognosis]] for patients with cervical cancer is generally good, and the 5 year [[survival rate]] of patients with cervical [[cancer]] is approximately 67.9%, this is heavily because of annual [[screening]] wiht [[Pap smear]] and introduction of new preventive methods like [[HPV]] [[vaccination]] to decrease the mortality and incidence rates. | |||
* Majority of cervical cancer cases can be detected early through the use of screening by [[Pap test]] and [[HPV]] [[DNA]] testing. | |||
* [[Prognosis]] of cervical cancer depends upon the [[clinical]] stage of the disease and distant [[metastasis]].<ref name="YuanWang1999">{{cite journal|last1=Yuan|first1=Chiou-Chung|last2=Wang|first2=Peng-Hui|last3=Lai|first3=Chiung-Ru|last4=Tsu|first4=En-Jie|last5=Yen|first5=Ming-Shyen|last6=Ng|first6=Heung-Tat|title=Recurrence and Survival Analyses of 1,115 Cervical Cancer Patients Treated with Radical Hysterectomy|journal=Gynecologic and Obstetric Investigation|volume=47|issue=2|year=1999|pages=127–132|issn=0378-7346|doi=10.1159/000010076}}</ref><ref name="B.K.B.2016">{{cite journal|last1=B.K.|first1=Vishma|last2=B.|first2=Prakash|last3=Kulkarni|first3=Praveen|last4=M.|first4=Renuka|title=Survival and prognostic factors for cervical cancer: a hospital based study in Mysuru, India|journal=International Journal of Community Medicine and Public Health|year=2016|pages=218–223|issn=2394-6032|doi=10.18203/2394-6040.ijcmph20151566}}</ref><ref name="JungWon2013">{{cite journal|last1=Jung|first1=Kyu-Won|last2=Won|first2=Young-Joo|last3=Kong|first3=Hyun-Joo|last4=Oh|first4=Chang-Mo|last5=Shin|first5=Aesun|last6=Lee|first6=Jin-Soo|title=Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study|journal=Cancer Research and Treatment|volume=45|issue=3|year=2013|pages=162–171|issn=1598-2998|doi=10.4143/crt.2013.45.3.162}}</ref> | |||
* These prognostic factors that affecting [[survival rate]] are include:<ref name="EndoTodo2015">{{cite journal|last1=Endo|first1=Daisuke|last2=Todo|first2=Yukiharu|last3=Okamoto|first3=Kazuhira|last4=Minobe|first4=Shinichiro|last5=Kato|first5=Hidenori|last6=Nishiyama|first6=Noriaki|title=Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort|journal=Journal of Gynecologic Oncology|volume=26|issue=1|year=2015|pages=12|issn=2005-0380|doi=10.3802/jgo.2015.26.1.12}}</ref> | |||
::* [[Patient]] age | |||
::* Maximum [[tumor]] diameter of ≥6 cm | |||
::* [[Pelvic]] [[lymph node]] enlargement, and distant [[metastasis]] | |||
::* Pretreatment [[hemoglobin]] level | |||
::* Concurrent chemoradiotherapy, increases [[survival rate]] significantly in patients with advanced stage of [[cervical]] cancer in comparison with those receiving [[radiation]] therapy alone | |||
::* Overal treatment period | |||
::* [[Clinical]] stage | |||
* Other prognostic factors are include:<ref name="KangKim2011">{{cite journal|last1=Kang|first1=Woo Dae|last2=Kim|first2=Cheol Hong|last3=Cho|first3=Moon Kyoung|last4=Kim|first4=Jong Woon|last5=Cho|first5=Hye Yon|last6=Kim|first6=Yoon Ha|last7=Choi|first7=Ho Sun|last8=Kim|first8=Seok Mo|title=HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB–IIA cervical cancer undergoing radical hysterectomy|journal=Gynecologic Oncology|volume=121|issue=3|year=2011|pages=546–550|issn=00908258|doi=10.1016/j.ygyno.2011.01.015}}</ref><ref name="pmid8093678">{{cite journal |vauthors=Maiman M, Fruchter RG, Guy L, Cuthill S, Levine P, Serur E |title=Human immunodeficiency virus infection and invasive cervical carcinoma |journal=Cancer |volume=71 |issue=2 |pages=402–6 |date=January 1993 |pmid=8093678 |doi= |url=}}</ref><ref name="KüblerHeinenberg2015">{{cite journal|last1=Kübler|first1=Kirsten|last2=Heinenberg|first2=Sally|last3=Rudlowski|first3=Christian|last4=Keyver-Paik|first4=Mignon-Denise|last5=Abramian|first5=Alina|last6=Merkelbach-Bruse|first6=Sabine|last7=Büttner|first7=Reinhard|last8=Kuhn|first8=Walther|last9=Schildhaus|first9=Hans-Ulrich|title=<i>c-myc</i> copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia|journal=Oncotarget|volume=6|issue=2|year=2015|issn=1949-2553|doi=10.18632/oncotarget.2706}}</ref> | |||
::* [[Human immunodeficiency virus]] ([[HIV]]) status: Women with [[HIV]] have more aggressive and advanced disease and a poorer [[prognosis]]. | |||
::* [[C-myc]] [[overexpression]]: A study of patients with known invasive [[squamous carcinoma]] of the [[cervix]] found that overexpression of the [[C-myc]] [[oncogene]] was associated with a poorer prognosis. | |||
::* [[HPV]]-18 [[DNA]] has been found to be an independent adverse [[molecular]] prognostic factor, studies have shown a worse outcome when [[HPV]]-18 was identified in cervical cancers of patients undergoing radical [[hysterectomy]] and [[pelvic]] [[lymphadenectomy]]. | |||
==Refrences== | |||
{{Reflist|2}} | |||
== | |||
{{ | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Gynecology]] | [[Category:Gynecology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
Latest revision as of 20:51, 29 July 2020
|
Cervical cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cervical cancer natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Cervical cancer natural history, complications and prognosis |
|
FDA on Cervical cancer natural history, complications and prognosis |
|
CDC on Cervical cancer natural history, complications and prognosis |
|
Cervical cancer natural history, complications and prognosis in the news |
|
Blogs on Cervical cancer natural history, complications and prognosis |
|
Risk calculators and risk factors for Cervical cancer natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
Overview
Cervical cancer is the most common cancer mainly among women in developing countries, there is an estimate of almost 260,000 deaths annually, about 80% occurred in developing countries. Common complications of cervical cancer include pain, vaginal bleeding, fistula and renal failure. Prognosis is generally good, and the 5 year survival rate of patients with cervical cancer is approximately 70%. Studies has proven that there is an association between age of the patients and socioeconomic status of women with higher incidence of infection with high risk HPV in underserved poulation in the US.
Natural history
- Cervical cancer is the most common cancer mainly among women in developing countries, there is an estimate of almost 260,000 deaths annually, about 80% occurred in developing countries.[1]
- Infection by high risk strain of oncogenic HPV types is an established cause of neoplastic lesions of the cervix, vagina and vulva, anus, penis and oropharynx. HPV 16 and 18, are the most common cause of approximately 70% of all cervical cancers worldwide. HPV is highly transmissible through direct skin to skin contact and intercourse, women with persistent high-risk HPV infections are at greatest risk for developing cervical cancer.
- Since the identification of HPV as main cause of cervical cancer, prevention strategies had been developed by the introduction of HPV testing and cytology screening and utilizing HPV vaccines in preadolescent girls and young women whom are at greater risk.[2]
- The most important risk factors associated with the infection by HPV are sexual intercourse at early age at the start of the first sexual relationships, having high number of sexual partners throughout life, or women being with men having multiple sexual partners. Male circumcision and use of condoms are factors that can reduce, but not preventing the transmission of human papilloma virus.[3]
- There is an association between age and socioeconomic status of women in underserved areas of the US and higher incidence of infection with HPV. [4]
Complications
Advanced stage of cervical cancer can cause varieties of complications, some of these are include:[5]
- Pain
- Vaginal hemorrhage
- Enterovaginal, rectovaginal, and vesico- or ureterovaginal fistulas
- Renal failure and/or uremia
- Malnutrition
- Anemia
- Mental depression
Prognosis
- The prognosis for patients with cervical cancer is generally good, and the 5 year survival rate of patients with cervical cancer is approximately 67.9%, this is heavily because of annual screening wiht Pap smear and introduction of new preventive methods like HPV vaccination to decrease the mortality and incidence rates.
- Majority of cervical cancer cases can be detected early through the use of screening by Pap test and HPV DNA testing.
- Prognosis of cervical cancer depends upon the clinical stage of the disease and distant metastasis.[6][7][8]
- These prognostic factors that affecting survival rate are include:[9]
- Patient age
- Maximum tumor diameter of ≥6 cm
- Pelvic lymph node enlargement, and distant metastasis
- Pretreatment hemoglobin level
- Concurrent chemoradiotherapy, increases survival rate significantly in patients with advanced stage of cervical cancer in comparison with those receiving radiation therapy alone
- Overal treatment period
- Clinical stage
- Human immunodeficiency virus (HIV) status: Women with HIV have more aggressive and advanced disease and a poorer prognosis.
- C-myc overexpression: A study of patients with known invasive squamous carcinoma of the cervix found that overexpression of the C-myc oncogene was associated with a poorer prognosis.
- HPV-18 DNA has been found to be an independent adverse molecular prognostic factor, studies have shown a worse outcome when HPV-18 was identified in cervical cancers of patients undergoing radical hysterectomy and pelvic lymphadenectomy.
Refrences
- ↑ Sherris J, Herdman C, Elias C (October 2001). "Cervical cancer in the developing world". West. J. Med. 175 (4): 231–3. PMC 1071564. PMID 11577044.
- ↑ Bosch, F. Xavier; Broker, Thomas R.; Forman, David; Moscicki, Anna-Barbara; Gillison, Maura L.; Doorbar, John; Stern, Peter L.; Stanley, Margaret; Arbyn, Marc; Poljak, Mario; Cuzick, Jack; Castle, Philip E.; Schiller, John T.; Markowitz, Lauri E.; Fisher, William A.; Canfell, Karen; Denny, Lynette A.; Franco, Eduardo L.; Steben, Marc; Kane, Mark A.; Schiffman, Mark; Meijer, Chris J.L.M.; Sankaranarayanan, Rengaswamy; Castellsagué, Xavier; Kim, Jane J.; Brotons, Maria; Alemany, Laia; Albero, Ginesa; Diaz, Mireia; Sanjosé, Silvia de (2013). "Comprehensive Control of Human Papillomavirus Infections and Related Diseases". Vaccine. 31: I1–I31. doi:10.1016/j.vaccine.2013.07.026. ISSN 0264-410X.
- ↑ Castellsagué, Xavier (2008). "Natural history and epidemiology of HPV infection and cervical cancer". Gynecologic Oncology. 110 (3): S4–S7. doi:10.1016/j.ygyno.2008.07.045. ISSN 0090-8258.
- ↑ Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, Jaggi M, Chauhan SC (June 2017). "Disparity in rates of HPV infection and cervical cancer in underserved US populations". Front Biosci (Schol Ed). 9: 254–269. PMC 5935458. PMID 28410118.
- ↑ Schmitz, Herbert E.; Isaacs, John H. (1957). "Complications of Advanced Cervical Cancer and Their Management". Radiology. 69 (3): 324–329. doi:10.1148/69.3.324. ISSN 0033-8419.
- ↑ Yuan, Chiou-Chung; Wang, Peng-Hui; Lai, Chiung-Ru; Tsu, En-Jie; Yen, Ming-Shyen; Ng, Heung-Tat (1999). "Recurrence and Survival Analyses of 1,115 Cervical Cancer Patients Treated with Radical Hysterectomy". Gynecologic and Obstetric Investigation. 47 (2): 127–132. doi:10.1159/000010076. ISSN 0378-7346.
- ↑ B.K., Vishma; B., Prakash; Kulkarni, Praveen; M., Renuka (2016). "Survival and prognostic factors for cervical cancer: a hospital based study in Mysuru, India". International Journal of Community Medicine and Public Health: 218–223. doi:10.18203/2394-6040.ijcmph20151566. ISSN 2394-6032.
- ↑ Jung, Kyu-Won; Won, Young-Joo; Kong, Hyun-Joo; Oh, Chang-Mo; Shin, Aesun; Lee, Jin-Soo (2013). "Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study". Cancer Research and Treatment. 45 (3): 162–171. doi:10.4143/crt.2013.45.3.162. ISSN 1598-2998.
- ↑ Endo, Daisuke; Todo, Yukiharu; Okamoto, Kazuhira; Minobe, Shinichiro; Kato, Hidenori; Nishiyama, Noriaki (2015). "Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort". Journal of Gynecologic Oncology. 26 (1): 12. doi:10.3802/jgo.2015.26.1.12. ISSN 2005-0380.
- ↑ Kang, Woo Dae; Kim, Cheol Hong; Cho, Moon Kyoung; Kim, Jong Woon; Cho, Hye Yon; Kim, Yoon Ha; Choi, Ho Sun; Kim, Seok Mo (2011). "HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB–IIA cervical cancer undergoing radical hysterectomy". Gynecologic Oncology. 121 (3): 546–550. doi:10.1016/j.ygyno.2011.01.015. ISSN 0090-8258.
- ↑ Maiman M, Fruchter RG, Guy L, Cuthill S, Levine P, Serur E (January 1993). "Human immunodeficiency virus infection and invasive cervical carcinoma". Cancer. 71 (2): 402–6. PMID 8093678.
- ↑ Kübler, Kirsten; Heinenberg, Sally; Rudlowski, Christian; Keyver-Paik, Mignon-Denise; Abramian, Alina; Merkelbach-Bruse, Sabine; Büttner, Reinhard; Kuhn, Walther; Schildhaus, Hans-Ulrich (2015). "c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia". Oncotarget. 6 (2). doi:10.18632/oncotarget.2706. ISSN 1949-2553.